OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases May 9, 2022
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms May 2, 2022
Pfizer and OPKO’s Once-Weekly NGENLATM (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency Feb 15, 2022
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency Jan 21, 2022
JAPAN’S MHLW APPROVES PFIZER AND OPKO’S NGENLA® (SOMATROGON), A NEW LONG-ACTING TREATMENT FOR PEDIATRIC GROWTH HORMONE DEFICIENCY Jan 20, 2022
